Craft

aTyr Pharma

Stock Price

$2.1

2023-03-01

Market Capitalization

$59.8 M

2023-03-01

Revenue

$10.4 M

FY, 2022

aTyr Pharma Summary

Company summary

Overview
aTyr Pharma develops biologic therapeutics based on Physiocrine biology. The Company has established a dominant intellectual property estate surrounding Physiocrine-based compositions and potential therapeutic applications. The Company's key programs are focused on immunomodulation disorders in the areas of inflammation and immunity and are in preclinical development.
Type
Public
Status
Active
Founded
2005
HQ
San Diego, CA, US | view all locations
Website
http://www.atyrpharma.com/
Cybersecurity rating
Sectors

Key people

  • John K. Clarke

    John K. Clarke, Chairman

    • Sanjay S. Shukla

      Sanjay S. Shukla, President and CEO, Director

      • Jill Broadfoot

        Jill Broadfoot, Chief Financial Officer

        • Nancy Denyes

          Nancy Denyes, General Counsel

          LocationsView all

          1 location detected

          • San Diego, CA HQ

            United States

            3545 John Hopkins Ct

          aTyr Pharma Financials

          Summary financials

          Revenue (FY, 2022)
          $10.4M
          Net income (FY, 2022)
          ($45.3M)
          Cash (FY, 2022)
          $10.0M
          EBIT (FY, 2022)
          ($46.4M)

          Footer menu